证券日报网讯 12月26日，联环药业发布公告称，公司控股子公司新乡市常乐制药有限责任公司于近日 收到国家药品监督管理局核准签发的《药品注册证书》，药品名称：美阿沙坦钾片。 （文章来源：证券日报） ...

本次常乐制药获得美阿沙坦钾片(40mg/80mg)《药品注册证书》，进一步丰富了公司及子公司的产品 线，有助于提升公司及子公司产品的市场竞争力。上述《药品注册证书》的取得预计不会对公司及子公 司近期经营业绩产生重大影响。 智通财经APP讯，联环药业(600513.SH)发布公告，公司控股子公司新乡市常乐制药有限责任公司(简 称"常乐制药")于近日收到国家药品监督管理局核准签发的美阿沙坦钾片《药品注册证书》。美阿沙坦 钾片可用于治疗成人原发性高血压。 ...

人民财讯12月26日电，联环药业（600513）12月26日公告，控股子公司常乐制药近日收到国家药监局核 准签发的美阿沙坦钾片《药品注册证书》，美阿沙坦钾片可用于治疗成人原发性高血压。 ...

联环药业12月26日公告，公司控股子公司常乐制药收到国家药监局核准签发的美阿沙坦钾片 （40mg/80mg）《药品注册证书》。该药品用于治疗成人原发性高血压，常乐制药美阿沙坦钾片 （40mg/80mg）研发投入约为人民币1099万元。截至公告披露日，常乐制药已获得10个生产批件。此次 获得《药品注册证书》预计不会对公司近期经营业绩产生重大影响。 ...

2024年8月，常乐制药首次递交美阿沙坦钾片(40mg/80mg)注册申请并获受理，近日常乐制药收到国家药 监局核准签发的美阿沙坦钾片(40mg/80mg)《药品注册证书》。常乐制药美阿沙坦钾片(40mg/80mg)按照 化学药品4类进行申报，根据国家相关政策，本次获得《药品注册证书》视同通过仿制药质量和疗效一 致性评价。 截至本公告披露日，常乐制药美阿沙坦钾片(40mg/80mg)研发投入约为人民币1099.00万元(未经审计)。 截至本公告披露日，常乐制药已经获得10个生产批件。 格隆汇12月26日丨联环药业(600513.SH)公布，公司控股子公司新乡市常乐制药有限责任公司于近日收 到国家药品监督管理局核准签发的《药品注册证书》。 美阿沙坦钾片可用于治疗成人原发性高血压。2024 年度全国样本医院美阿沙坦钾片销售额达5873.19万 元(数据来源于摩熵·医药数据库)。 本次常乐制药获得美阿沙坦钾片(40mg/80mg)《药品注册证书》，进一步丰富了公司及子公司的产品 线，有助于提升公司及子公司产品的市场竞争力。上述《药品注册证书》的取得预计不会对公司及子公 司近期经营业绩产生重大影响。 财经频道更多独家 ...

每经AI快讯，12月26日，联环药业(600513.SH)公告称，公司控股子公司常乐制药收到国家药监局核准 签发的美阿沙坦钾片（40mg/80mg）《药品注册证书》。该药品用于治疗成人原发性高血压，常乐制药 美阿沙坦钾片（40mg/80mg）研发投入约为人民币1099万元。截至公告披露日，常乐制药已获得10个生 产批件。此次获得《药品注册证书》预计不会对公司近期经营业绩产生重大影响。 （文章来源：每日经济新闻） ...

证券日报网12月25日讯，联环药业（600513）在接受投资者提问时表示，公司将研发创新作为核心战 略，研发投入重点向创新药、改良新药及具有技术壁垒的仿制药倾斜，逐步压缩普通仿制药的研发投 入。目前公司在手6个创新药研发项目，核心项目LH-1801(SGLT-2抑制剂)处于Ⅲ期临床试验52周随访阶 段，预计2026年一季度揭盲，该类药物在糖化血红蛋白控制及心衰、肾脏保护方面具有差异化优势，未 来市场空间广阔。此外，治疗急性髓系白血病的LH-1802处于临床试验阶段，治疗慢性阻塞性肺疾病的 LH-1901已启动I期临床试验。公司依托院士工作站、博士工作站，与中国科学院上海药研所、中国药科 大学、浙江大学等知名科研院所和高等院校深度合作。截至目前，2025年共获得13个生产批件，2个临 床批件，其中公司为通过甲磺酸酚妥拉明注射液(1ml：10mg)一致性评价(含视同)的两家之一；为国内 美阿沙坦钾片三家上市厂家之一；为全国首家盐酸屈他维林片通过一致性评价的企业(以公告披露日为 准)。 ...

Core Viewpoint - Fosen Pharmaceutical (01652) shares rose over 7% following the approval of its hypertension treatment, "Mei Asha Tan Potassium Tablets," by the National Medical Products Administration of China [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., developed "Mei Asha Tan Potassium Tablets," which have received regulatory approval for the treatment of primary hypertension [1] - The active ingredient, Mei Asha Tan Potassium, is an angiotensin II receptor antagonist that converts rapidly to the active component Azilsartan upon oral absorption, effectively lowering blood pressure by blocking the angiotensin II hormone [1] Industry Summary - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 100 billion RMB in 2022 [1] - "Sartan" medications play a crucial role within the family of antihypertensive drugs, indicating strong market demand and potential for growth in this segment [1]

Core Viewpoint - Fosen Pharmaceutical (01652) shares rose over 7% following the approval of its hypertension treatment, "Mei Asha Tan Potassium Tablets," by the National Medical Products Administration of China [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., received approval for "Mei Asha Tan Potassium Tablets," which are indicated for the treatment of primary hypertension [1] - The active ingredient, Mei Asha Tan Potassium, is an angiotensin II receptor antagonist that converts rapidly to the active component Azilsartan upon oral absorption, effectively lowering blood pressure by blocking the angiotensin II hormone [1] Industry Summary - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 100 billion RMB in 2022 [1] - "Sartan" drugs play a crucial role within the family of antihypertensive medications, indicating strong market demand and potential for growth in this segment [1]

Core Insights - The company has received approval from the National Medical Products Administration of China for its product "Mebsartan Potassium Tablets" (trademark: Kuanopeng), which is indicated for the treatment of primary hypertension [1][2] - "Mebsartan Potassium" is a significant addition to the company's product pipeline in the cardiovascular system sector, providing more treatment options for adult patients with primary hypertension [2] Group 1: Product Details - "Mebsartan Potassium" is an angiotensin II receptor antagonist that converts rapidly to its active form, Azilsartan, after oral administration, effectively lowering blood pressure by blocking angiotensin II hormone [1] - The product is classified as a Category B drug by the National Medical Insurance Administration, with no restrictions on insurance indications or disease types, making it a first-line antihypertensive medication for adults [1] Group 2: Market Context - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 10 billion RMB in 2022, highlighting its importance in the hypertension drug family [1] - The company’s "Mebsartan Potassium Tablets" are available in 40mg and 80mg dosages, catering to both mild to moderate and severe hypertension patients [2]